{"result": "(\"entity\"<|>CIRROSIS<|>EVENT<|>Cirrhosis is a late stage of scarring (fibrosis) of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcoholism, which can lead to malnutrition and complications requiring transplantation.)\n##\n(\"entity\"<|>SÍNDROME METABÓLICO<|>EVENT<|>Metabolic syndrome is a cluster of conditions that increase the risk of heart disease, stroke, and diabetes, often associated with obesity and sarcopenia in patients post-liver transplantation.)\n##\n(\"entity\"<|>NUTRICIÓN ENTERAL<|>EVENT<|>Enteral nutrition is a method of delivering nutrients directly into the gastrointestinal tract, which may be necessary for patients unable to consume food orally, particularly in the context of liver disease.)\n##\n(\"entity\"<|>HÁBITOS DE VIDA SALUDABLE<|>EVENT<|>Healthy lifestyle habits include a balanced diet and regular physical activity, which are recommended to prevent obesity and sarcopenia in patients post-liver transplantation.)\n##\n(\"relationship\"<|>CIRROSIS<|>MALNUTRICIÓN<|>Cirrhosis can lead to malnutrition due to inadequate nutrient intake and metabolic dysfunction<|>8)\n##\n(\"relationship\"<|>CIRROSIS<|>SARCOPENIA<|>Cirrhosis is associated with the development of sarcopenia due to muscle wasting and metabolic changes<|>7)\n##\n(\"relationship\"<|>SÍNDROME METABÓLICO<|>OBESIDAD<|>Metabolic syndrome is often characterized by obesity and can develop in patients post-liver transplantation<|>6)\n##\n(\"relationship\"<|>NUTRICIÓN ENTERAL<|>MALNUTRICIÓN<|>Enteral nutrition is often used to address malnutrition in patients who cannot eat normally<|>7)\n##\n(\"relationship\"<|>HÁBITOS DE VIDA SALUDABLE<|>OBESIDAD<|>Healthy lifestyle habits are promoted to prevent obesity, especially in patients post-liver transplantation<|>5)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: en pacientes en los que no es posible la nutrición enteral. Debe contener\n  todos los principios inmediatos.\n  Después del trasplante se debe evitar el exceso de aporte nutricional.\n  Se debe realizar seguimiento postrasplante para detectar, prevenir y tratar el desarrollo de obesidad, sarcopenia,\n  hiperlipemia, hipertensión y osteoporosis.\n---\n                                           Tema 16.     Soporte nutricional en la hepatopatía crónica y trasplante hepático                    281\n\n\n\n   Los mecanismos subyacentes a este hecho no están                                 tic encephalopathy: results of a prospective study.\naclarados. Los inhibidores directos de mTORC1 blo-                                  Metab Brain Dis 2013;28:281-284.\nquean la síntesis proteica y son de uso generalizado en                         4.  Dasarathy S. Consilience in sarcopenia of cirrhosis.\npostrasplante. La hipertrofia muscular está mediada                                 J Cachexia Sarcopenia Muscle 2012;3:225-237.\npor calcineurina y los inhibidores de la misma también                          5.  Montano-Loza AJ, Meza-Junco J, Baracos VE, et\nse usan ampliamente en postrasplante hepático. La                                   al. Severe muscle depletion predicts postoperative\ncontribución de estos fármacos a la obesidad y sarco-                               length of stay but is not associated with survival\npenia, ha de ser aún evaluada. Es posible que cambios                               after   liver  transplantation.       Liver  Transpl.     2014\nepigenéticos en moléculas reguladoras tengan como                                   Jun;20(6):640-8.\nconsecuencia sarcopenia persistente después del tras-                           6.  Tandon P, Ney M, Irwin I, Ma MM, Gramlich L,\nplante y de descenso de amoniemia. Son aspectos que                                 Bain VG, et al. Severe muscle depletion in patients\nrequieren estudio.                                                                  on the liver transplant wait list: its prevalence and\n   Las consecuencias de desarrollo a largo plazo de sar-                            independent        prognostic       value.    Liver    Transpl\ncopenia y obesidad sarcopénica son también mal co-                                  2012;18:1209-1216.\nnocidas. Parece asociarse a síndrome metabólico, insu-                          7.  Hara N, Iwasa M, Sugimoto R, Mifuji-Moroka R,\nlino-resistencia y eventos cardiovasculares. Un 38% de                              Yoshikawa K, Terasaka E,           et al.   Sarcopenia and\nlos pacientes desarrollan síndrome metabólico 5 años                                sarcopenic obesity are prognostic factors for ove-\ndespués del trasplante164. Deberían promoverse hábi-                                rall survival in patients with cirrhosis. Intern Med\ntos de vida saludable, incluyendo dieta saludable evi-                              2016;55:863-870.\ntando el exceso de energía, grasa y sal165.                                     8.  Montano-Loza AJ, Duarte-Rojo A, Meza-Junco J.\n                                                                                    Inclusion of Sarcopenia Within MELD (MELD-Sar-\n                                                                                    copenia) and the Prediction of Mortality in Patients\n13.    Resumen y conclusiones                                                       With Cirrhosis. Clin Transl Gastroenterol. 2015;\n   La malnutrición es un importante factor pronóstico                               6(7): e102.\nque puede influenciar el curso clínico de pacientes con                         9.  Montano-Loza AJ Muscle wasting: a nutritional\nEHCA. Su presencia debería alertar a los clínicos tanto                             criterion to prioritize patients for liver transplanta-\ncomo la ascitis y la encefalopatía. Los mecanismos fi-                              tion.   Curr   Opin    Clin    Nutr   Metab      Care.    2014\nsiopatológicos que llevan a la situación de malnutrición                            May;17(3):219-25.\nen pacientes con cirrosis hepática son múltiples e inte-                      10.   Carias S, Castellanos AL, Vilchez V et al. Nonalco-\nractúan entre sí. Entre ellos podemos mencionar la in-                              holic steatohepatitis is strongly associated with\ngesta inadecuada de nutrientes, alteraciones metabóli-                              sarcopenic obesity in patients with cirrhosis under-\ncas hepáticas y musculares y alteración de la absorción                             going liver transplant evaluation. J Gastroenterol\nde nutrientes. Es conveniente disponer de herramien-                                Hepatol. 2016 Mar;31(3):628-33.\ntas sencillas para identificar el estado de malnutrición                      11.   Periyalwar P, Dasarathy S. Malnutrition in cirrhosis:\nen estos pacientes, con el fin de proporcionar soporte                              contribution and consequences of sarcopenia on\nnutricional adecuado. La ingesta de 4 a 6 tomas de                                  metabolic and clinical responses. Clin Liver Dis.\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>HEPATOPATÍA CRÓNICA<|>EVENT<|>Hepatopatía crónica refers to chronic liver disease, which can lead to complications requiring nutritional support and liver transplantation.)\n##\n(\"entity\"<|>TRASPLANTE HEPÁTICO<|>EVENT<|>Liver transplantation is a surgical procedure to replace a diseased liver with a healthy liver from a donor, often necessitating nutritional management post-surgery.)\n##\n(\"entity\"<|>SARCOPENIA<|>EVENT<|>Sarcopenia is the loss of muscle mass and strength, often observed in patients with chronic liver disease and post-liver transplantation.)\n##\n(\"entity\"<|>MALNUTRICIÓN<|>EVENT<|>Malnutrition is a significant prognostic factor that can influence the clinical course of patients with chronic liver disease, affecting their eligibility for liver transplantation.)\n##\n(\"entity\"<|>OBESIDAD<|>EVENT<|>Obesity is a condition that can develop post-liver transplantation and is associated with various metabolic complications.)\n##\n(\"entity\"<|>CALCINEURINA<|>ORGANIZATION<|>Calcineurina is a protein phosphatase involved in muscle hypertrophy and is targeted by immunosuppressive drugs used in post-liver transplantation care.)\n##\n(\"entity\"<|>INHIBIDORES DE mTORC1<|>ORGANIZATION<|>Inhibidores de mTORC1 are drugs that block protein synthesis and are commonly used in post-transplant care to manage complications.)\n##\n(\"relationship\"<|>HEPATOPATÍA CRÓNICA<|>MALNUTRICIÓN<|>Chronic liver disease can lead to malnutrition due to inadequate nutrient intake and metabolic alterations<|>8)\n##\n(\"relationship\"<|>TRASPLANTE HEPÁTICO<|>SARCOPENIA<|>Sarcopenia is a common complication observed in patients after liver transplantation<|>7)\n##\n(\"relationship\"<|>SARCOPENIA<|>OBESIDAD<|>Sarcopenia and obesity can coexist in patients post-liver transplantation, leading to sarcopenic obesity<|>6)\n##\n(\"relationship\"<|>TRASPLANTE HEPÁTICO<|>OBESIDAD<|>Obesity can develop as a long-term consequence of liver transplantation, affecting patient outcomes<|>5)\n##\n(\"relationship\"<|>CALCINEURINA<|>SARCOPENIA<|>Calcineurina inhibitors are used in post-transplant care and may influence the development of sarcopenia<|>4)\n##\n(\"relationship\"<|>INHIBIDORES DE mTORC1<|>SARCOPENIA<|>mTORC1 inhibitors are used in post-transplant care and may impact muscle mass and sarcopenia<|>4)\n<|COMPLETE|>"}]}